HUP0301269A3 - Phthalazinone derivatives and pharmaceutical compositions containing them - Google Patents
Phthalazinone derivatives and pharmaceutical compositions containing themInfo
- Publication number
- HUP0301269A3 HUP0301269A3 HU0301269A HUP0301269A HUP0301269A3 HU P0301269 A3 HUP0301269 A3 HU P0301269A3 HU 0301269 A HU0301269 A HU 0301269A HU P0301269 A HUP0301269 A HU P0301269A HU P0301269 A3 HUP0301269 A3 HU P0301269A3
- Authority
- HU
- Hungary
- Prior art keywords
- pharmaceutical compositions
- compositions containing
- phthalazinone derivatives
- phthalazinone
- derivatives
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- IJAPPYDYQCXOEF-UHFFFAOYSA-N phthalazin-1(2H)-one Chemical class C1=CC=C2C(=O)NN=CC2=C1 IJAPPYDYQCXOEF-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0026505.8A GB0026505D0 (en) | 2000-10-30 | 2000-10-30 | Phthalazinone derivatives |
| US27506601P | 2001-03-12 | 2001-03-12 | |
| PCT/GB2001/004729 WO2002036576A1 (en) | 2000-10-30 | 2001-10-25 | Phthalazinone derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| HUP0301269A2 HUP0301269A2 (hu) | 2003-12-29 |
| HUP0301269A3 true HUP0301269A3 (en) | 2004-03-29 |
| HU228960B1 HU228960B1 (hu) | 2013-07-29 |
Family
ID=26245211
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0301269A HU228960B1 (hu) | 2000-10-30 | 2001-10-25 | Ftalazinon-származékok |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1330442B1 (hu) |
| JP (1) | JP2009149643A (hu) |
| KR (1) | KR100804564B1 (hu) |
| CN (1) | CN100400518C (hu) |
| AU (2) | AU2001295789B2 (hu) |
| BR (1) | BR0115062A (hu) |
| CA (1) | CA2423279C (hu) |
| CY (1) | CY1111380T1 (hu) |
| EA (1) | EA006300B1 (hu) |
| GB (1) | GB2384776C (hu) |
| HK (1) | HK1056880A1 (hu) |
| HU (1) | HU228960B1 (hu) |
| IL (2) | IL155645A0 (hu) |
| MX (1) | MXPA03003218A (hu) |
| NO (1) | NO325637B1 (hu) |
| NZ (1) | NZ525138A (hu) |
| PL (1) | PL223343B1 (hu) |
| WO (1) | WO2002036576A1 (hu) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7151102B2 (en) | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| JP4500161B2 (ja) * | 2002-04-30 | 2010-07-14 | クドス ファーマシューティカルズ リミテッド | フタラジノン誘導体 |
| US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| GB0305681D0 (en) | 2003-03-12 | 2003-04-16 | Kudos Pharm Ltd | Phthalazinone derivatives |
| GB2415430B (en) * | 2003-03-12 | 2006-07-12 | Kudos Pharm Ltd | Phthalazinone derivatives |
| TW200505441A (en) * | 2003-03-24 | 2005-02-16 | Hoffmann La Roche | Non-nucleoside reverse transcriptase inhibitorsⅠ |
| EP2385041B1 (en) | 2003-05-01 | 2013-09-18 | Bristol-Myers Squibb Company | Pyrazole-amine compounds useful as kinase inhibitors |
| GB0317466D0 (en) | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
| CN1905864B (zh) * | 2003-12-01 | 2011-04-06 | 库多斯药物有限公司 | 用于治疗癌症的dna损伤修复抑制剂 |
| RU2413515C2 (ru) | 2003-12-01 | 2011-03-10 | Кудос Фармасьютикалс Лимитед | Ингибиторы репарации повреждения днк для лечения рака |
| EP1771175B1 (en) * | 2004-06-30 | 2015-12-23 | Janssen Pharmaceutica NV | Phthalazine derivatives as parp inhibitors |
| MX2007002318A (es) * | 2004-08-26 | 2007-04-17 | Kudos Pharm Ltd | Derivados de ftalazinona substituidos con 4-heteroarilmetilo. |
| GB0419072D0 (en) | 2004-08-26 | 2004-09-29 | Kudos Pharm Ltd | Phthalazinone derivatives |
| GB0428111D0 (en) * | 2004-12-22 | 2005-01-26 | Kudos Pharm Ltd | Pthalazinone derivatives |
| GB0521373D0 (en) * | 2005-10-20 | 2005-11-30 | Kudos Pharm Ltd | Pthalazinone derivatives |
| JP5271897B2 (ja) | 2006-05-31 | 2013-08-21 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ | ポリ（ＡＤＰ−リボース）ポリメラーゼ（ＰＡＲＰ）の阻害剤としての、ピロロ［１，２−ａ］ピラジン−１（２Ｈ）−オン及びピロロ［１，２−ｄ］［１，２，４］トリアジン−１（２Ｈ）−オン誘導体 |
| GB0610680D0 (en) | 2006-05-31 | 2006-07-12 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
| TWI404716B (zh) * | 2006-10-17 | 2013-08-11 | Kudos Pharm Ltd | 酞嗪酮（ｐｈｔｈａｌａｚｉｎｏｎｅ）衍生物 |
| US20080280910A1 (en) * | 2007-03-22 | 2008-11-13 | Keith Allan Menear | Phthalazinone derivatives |
| GB0716532D0 (en) | 2007-08-24 | 2007-10-03 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| AU2008299721A1 (en) | 2007-09-14 | 2009-03-19 | Astrazeneca Ab | Phthalazinone derivatives |
| CN101821242B (zh) | 2007-10-17 | 2013-07-24 | 库多斯药物有限公司 | 4-[3-(4-环丙烷羰基-哌嗪-1-羰基)-4-氟-苄基]-2h-酞嗪-1-酮 |
| ES2524787T3 (es) | 2007-11-15 | 2014-12-12 | Msd Italia S.R.L. | Derivados de piridazinona como inhibidores de PARP |
| UY31603A1 (es) | 2008-01-23 | 2009-08-31 | Derivados de ftalazinona | |
| CN102238945B (zh) | 2008-10-07 | 2014-10-29 | 阿斯利康(英国)有限公司 | 药物制剂514 |
| KR101033492B1 (ko) * | 2009-01-22 | 2011-05-12 | 김기산 | 현수막 게시대 |
| WO2011058367A2 (en) | 2009-11-13 | 2011-05-19 | Astrazeneca Ab | Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor |
| WO2012014221A1 (en) | 2010-07-27 | 2012-02-02 | Cadila Healthcare Limited | Substituted 4-(4-fluoro-3-(piperazine-1- carbonyl)benzyl)phthalazin-1(2h)-one derivatives as poly (adp-ribose) polymerase- 1 inhibitors |
| CN102372716A (zh) | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| CN102485721B (zh) * | 2010-12-03 | 2015-12-09 | 曹亚 | 取代的2,3-二氮杂萘酮化合物及其用途 |
| EP3925962A1 (en) | 2011-05-31 | 2021-12-22 | Rakovina Therapeutics Inc. | Tricyclic inhibitors of poly(adp-ribose) polymerase |
| CN102344425B (zh) * | 2011-07-26 | 2014-04-09 | 兰州大学 | 一种合成含三氟甲基呋喃化合物的方法 |
| CN103130723B (zh) | 2011-11-30 | 2015-01-14 | 成都地奥制药集团有限公司 | 一种多聚(adp-核糖)聚合酶抑制剂 |
| CN102633732B (zh) * | 2012-03-08 | 2014-07-30 | 江苏先声药物研究有限公司 | 一类酞嗪酮衍生物及其应用 |
| EP2830608B8 (en) * | 2012-03-28 | 2020-01-15 | UCB Biopharma SRL | Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation |
| WO2014102817A1 (en) | 2012-12-31 | 2014-07-03 | Cadila Healthcare Limited | Substituted phthalazin-1 (2h)-one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1 |
| EA034395B1 (ru) | 2013-01-18 | 2020-02-04 | Бристол-Майерс Сквибб Компани | Фталазиноны и изохинолиноны в качестве ингибиторов rock |
| CA2906008C (en) * | 2013-03-13 | 2019-07-09 | Flatley Discovery Lab, Llc | Pyridazinone compounds and methods for the treatment of cystic fibrosis |
| SG11201510584WA (en) * | 2013-06-24 | 2016-01-28 | Merck Patent Gmbh | Phthalazine derivatives |
| KR101670126B1 (ko) | 2013-09-13 | 2016-10-27 | 일동제약(주) | 신규 프탈라지논 유도체 및 그 제조방법 |
| GB201317609D0 (en) | 2013-10-04 | 2013-11-20 | Cancer Rec Tech Ltd | Inhibitor compounds |
| US9902702B2 (en) | 2014-07-15 | 2018-02-27 | Bristol-Myers Squibb Company | Spirocycloheptanes as inhibitors of rock |
| US10202361B2 (en) | 2014-08-29 | 2019-02-12 | Fmc Corporation | Pyridazinones as herbicides |
| GB201505658D0 (en) | 2015-04-01 | 2015-05-13 | Cancer Rec Tech Ltd | Inhibitor compounds |
| CN106146492A (zh) * | 2015-04-17 | 2016-11-23 | 上海汇伦生命科技有限公司 | 杂环并咪唑类化合物、其药物组合物及其制备方法和用途 |
| WO2016187620A2 (en) | 2015-05-21 | 2016-11-24 | The Regents Of The University Of California | Anti-cancer compounds |
| WO2017013593A1 (en) | 2015-07-22 | 2017-01-26 | Lupin Limited | Isoquinolinone derivatives as parp inhibitors |
| EP3325623B3 (en) | 2015-07-23 | 2021-01-20 | Institut Curie | Use of a combination of dbait molecule and parp inhibitors to treat cancer |
| MX2018001871A (es) | 2015-08-17 | 2018-05-28 | Lupin Ltd | Derivados de heteroarilo como inhibidores de parp. |
| GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
| EP3475272B1 (en) | 2016-06-24 | 2023-09-13 | The Regents of The University of California | Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer |
| GB201617103D0 (en) | 2016-10-07 | 2016-11-23 | Cancer Research Technology Limited | Compound |
| CN107955001A (zh) | 2016-10-14 | 2018-04-24 | 上海汇伦生命科技有限公司 | 抗肿瘤杂环并咪唑类化合物的药用盐 |
| WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
| CN108358850B (zh) * | 2018-02-11 | 2021-01-26 | 中国药科大学 | PARP-1和Tankyrase1/2多靶点抑制剂、其制法及用途 |
| WO2019175132A1 (en) | 2018-03-13 | 2019-09-19 | Onxeo | A dbait molecule against acquired resistance in the treatment of cancer |
| GB201913030D0 (en) | 2019-09-10 | 2019-10-23 | Francis Crick Institute Ltd | Treatment of hr deficient cancer |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| MX2022013304A (es) | 2020-04-21 | 2022-12-15 | Idience Co Ltd | Formas cristalinas de compuesto de ftalazinona. |
| KR20230002487A (ko) | 2020-04-28 | 2023-01-05 | 리젠 파마슈티컬스 아게 | 폴리(adp-리보스) 폴리머라제(parp) 억제제로서 유용한 신규 화합물 |
| WO2021224381A1 (en) | 2020-05-07 | 2021-11-11 | Astrazeneca Ab | Combination therapy for treating cancer |
| WO2022090938A1 (en) | 2020-10-31 | 2022-05-05 | Rhizen Pharmaceuticals Ag | Phthalazinone derivatives useful as parp inhibitors |
| CN116635371A (zh) * | 2021-02-09 | 2023-08-22 | 苏州阿尔脉生物科技有限公司 | 一种作为sos1抑制剂的多环哒嗪酮类衍生物、其制备方法及用途 |
| MX2023011793A (es) | 2021-04-08 | 2023-10-12 | Rhizen Pharmaceuticals Ag | Inhibidores de poli(adenosin difosfato-ribosa) polimerasa. |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3274185A (en) * | 1963-10-08 | 1966-09-20 | S E Massengill Company | Phthalazine derivatives |
| GB8610018D0 (en) * | 1986-04-24 | 1986-05-29 | Fujisawa Pharmaceutical Co | Phthalazine derivatives |
| ES2067508T3 (es) * | 1988-08-19 | 1995-04-01 | Warner Lambert Co | Dihidroisoquinolinonas sustituidas y compuestos relacionados como potenciadores de los efectos letales de la radiacion y de ciertos agentes quimioterapeuticos; compuestos seleccionados, analogos y proceso. |
| DE19630250C1 (de) * | 1996-07-26 | 1997-08-28 | Krupp Vdm Gmbh | Vollmetallischer Oxidationskatalysator |
| CO4950519A1 (es) * | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| US5888529A (en) * | 1997-03-28 | 1999-03-30 | The Regents Of The University Of California | Ileus treatment method |
| KR20010101675A (ko) * | 1999-01-26 | 2001-11-14 | 우에노 도시오 | 2ｈ-프탈라진-1-온 유도체 및 그 유도체를 유효 성분으로하는 약제 |
| GB0026505D0 (en) * | 2000-10-30 | 2000-12-13 | Kudos Pharm Ltd | Phthalazinone derivatives |
-
2001
- 2001-10-25 EA EA200300531A patent/EA006300B1/ru not_active IP Right Cessation
- 2001-10-25 PL PL360909A patent/PL223343B1/pl unknown
- 2001-10-25 EP EP01976521A patent/EP1330442B1/en not_active Expired - Lifetime
- 2001-10-25 CN CNB018183573A patent/CN100400518C/zh not_active Expired - Lifetime
- 2001-10-25 AU AU2001295789A patent/AU2001295789B2/en active Active
- 2001-10-25 IL IL15564501A patent/IL155645A0/xx active IP Right Grant
- 2001-10-25 MX MXPA03003218A patent/MXPA03003218A/es active IP Right Grant
- 2001-10-25 GB GB0309190A patent/GB2384776C/en not_active Expired - Lifetime
- 2001-10-25 NZ NZ525138A patent/NZ525138A/en not_active IP Right Cessation
- 2001-10-25 CA CA2423279A patent/CA2423279C/en not_active Expired - Lifetime
- 2001-10-25 AU AU9578901A patent/AU9578901A/xx active Pending
- 2001-10-25 BR BR0115062-6A patent/BR0115062A/pt not_active Application Discontinuation
- 2001-10-25 WO PCT/GB2001/004729 patent/WO2002036576A1/en active IP Right Grant
- 2001-10-25 HU HU0301269A patent/HU228960B1/hu unknown
- 2001-10-25 KR KR1020037005963A patent/KR100804564B1/ko active Protection Beyond IP Right Term
-
2003
- 2003-04-02 NO NO20031498A patent/NO325637B1/no not_active IP Right Cessation
- 2003-04-29 IL IL155645A patent/IL155645A/en unknown
- 2003-12-19 HK HK03109260.1A patent/HK1056880A1/xx not_active IP Right Cessation
-
2008
- 2008-12-17 JP JP2008320616A patent/JP2009149643A/ja active Pending
-
2011
- 2011-04-05 CY CY20111100363T patent/CY1111380T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL155645A0 (en) | 2003-11-23 |
| NO325637B1 (no) | 2008-06-30 |
| AU2001295789B2 (en) | 2006-05-11 |
| CA2423279C (en) | 2011-07-05 |
| IL155645A (en) | 2008-04-13 |
| PL360909A1 (en) | 2004-09-20 |
| KR20030059811A (ko) | 2003-07-10 |
| GB2384776A (en) | 2003-08-06 |
| GB2384776B (en) | 2004-03-03 |
| CN100400518C (zh) | 2008-07-09 |
| HK1056880A1 (en) | 2004-03-05 |
| KR100804564B1 (ko) | 2008-02-20 |
| HUP0301269A2 (hu) | 2003-12-29 |
| NO20031498L (no) | 2003-04-02 |
| MXPA03003218A (es) | 2004-12-03 |
| EP1330442A1 (en) | 2003-07-30 |
| JP2009149643A (ja) | 2009-07-09 |
| EP1330442B1 (en) | 2011-01-19 |
| HU228960B1 (hu) | 2013-07-29 |
| BR0115062A (pt) | 2004-02-17 |
| CY1111380T1 (el) | 2015-08-05 |
| GB0309190D0 (en) | 2003-05-28 |
| AU9578901A (en) | 2002-05-15 |
| NZ525138A (en) | 2004-03-26 |
| CA2423279A1 (en) | 2002-05-10 |
| EA006300B1 (ru) | 2005-10-27 |
| EA200300531A1 (ru) | 2003-10-30 |
| PL223343B1 (pl) | 2016-10-31 |
| WO2002036576A1 (en) | 2002-05-10 |
| GB2384776C (en) | 2006-02-03 |
| AU2001295789C1 (en) | 2002-05-15 |
| CN1473154A (zh) | 2004-02-04 |
| NO20031498D0 (no) | 2003-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0301269A3 (en) | Phthalazinone derivatives and pharmaceutical compositions containing them | |
| IL152451A0 (en) | 2-chloro-2-nitrophenylcarboxamide derivatives and pharmaceutical compositions containing the same | |
| HUP0301178A3 (en) | Glucopyranosyloxybenzylbenzene derivatives and pharmaceutical compositions containing the same | |
| IL153123A0 (en) | N-ureidoheterocycloalkyl-piperidine derivatives and pharmaceutical compositions containing the same | |
| IL156368A0 (en) | Pyrazole derivatives and pharmaceutical compositions containing the same | |
| IL154786A0 (en) | Pyrazole derivatives and pharmaceutical compositions containing the same | |
| IL145757A0 (en) | Pyrazole derivatives and pharmaceutical compositions containing the same | |
| IL145756A0 (en) | Pyrazole derivatives and pharmaceutical compositions containing the same | |
| IL177018A0 (en) | Cyclopropyl-fused pyrrolidine derivatives and pharmaceutical compositions containing the same | |
| HUP0400837A3 (en) | 2-phenyl-thiazole derivatives, their use and pharmaceutical compositions containing them | |
| HUP0204474A3 (en) | 1h-imidazopyridine derivatives, pharmaceutical compositions containing them and their use | |
| IL161616A0 (en) | Indazolypyrrolotriazine derivatives and pharmaceutical compositions containing the same | |
| IL158044A0 (en) | Cyclopropylindole derivatives and pharmaceutical compositions containing the same | |
| IL158300A0 (en) | Bisarylimidazol derivatives and pharmaceutical compositions containing the same | |
| IL150449A0 (en) | Aniline derivatives and pharmaceutical compositions containing the same | |
| IL156812A0 (en) | Phthalazinone-piperidino derivatives and pharmaceutical compositions containing the same | |
| IL157908A0 (en) | Phthalazinone derivatives and pharmaceutical compositions containing the same | |
| IL152846A0 (en) | Pyridazinone derivatives and pharmaceutical compositions containing the same | |
| IL147214A0 (en) | 1-methylcarbapenem derivatives and pharmaceutical compositions containing the same | |
| HUP0303184A3 (en) | Substituted c-cyclohexylmethylamine derivatives and pharmaceutical compositions containing them | |
| HUP0200468A3 (en) | Resorcinol derivatives and pharmaceutical compositions containing them | |
| HUP0303204A3 (en) | 1-methylcarbapenem derivatives and pharmaceutical compositions containing them | |
| HUP0200088A3 (en) | Pyridazin-3-one derivatives and pharmaceutical compositions containing the same | |
| IL156372A0 (en) | Carbazole derivatives and pharmaceutical compositions containing the same | |
| AU4834101A (en) | N-deacetylthiocolchicine derivatives and pharmaceutical compositions containing them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB9A | Succession in title |
Owner name: KUDOS PHARMACEUTICALS LIMITED, GB Free format text: FORMER OWNER(S): KUDOS PHARMACEUTICALS LIMITED, GB; MAYBRIDGE PLC, GB |
|
| HC9A | Change of name, address |
Owner name: KUDOS PHARMACEUTICALS LIMITED, GB Free format text: FORMER OWNER(S): KUDOS PHARMACEUTICALS LIMITED, GB; MAYBRIDGE PLC, GB; KUDOS PHARMACEUTICALS LIMITED, GB |